Kodiak Sciences stock fell 4.07 percent on October 2 after DAYBREAK data

Published on 10/04/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kodiak Sciences stock is tied to a 54 percent six-month dosing rate from the September 28 DAYBREAK readout. Q2 EPS was USD -1.05.

KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences stock (ISIN US50015M1099) was last at USD 94.45 on Nasdaq on October 2, 2026, down 4.07 percent from the prior session. The central company event was the September 28 release of Phase 3 DAYBREAK results, in which Zenkuda and tabirafusp-ted met their primary endpoints, according to Kodiak Sciences.

DAYBREAK clears its main test

Zenkuda achieved non-inferior vision gains versus aflibercept at one year in wet age-related macular degeneration. The company reported a p-value of 0.0007 and said 54 percent of patients reached a six-month dosing interval at the one-year assessment.

Tabirafusp-ted also met its vision primary endpoint with a p-value of 0.0036 and its anatomical key secondary endpoint with a p-value below 0.0001. Kodiak said its Zenkuda data support a planned multi-indication biologics license application in Q4 2026, covering five positive Phase 3 studies, per the September 28 release from Kodiak Sciences.

Losses keep the story clinical

The latest reported quarter ended June 30, 2026. Kodiak posted adjusted? No, the reported diluted EPS was USD -1.05, versus consensus of USD -0.96, a USD 0.09 miss, according to MarketBeat. Operating cash flow was negative USD 46.238 million in Q2 2026, while net loss reached USD 65.643 million for the same period.

That financial profile leaves regulatory execution and funding discipline alongside the clinical readout. Kodiak remains a precommercial biotechnology company focused on retinal medicines, with Zenkuda, tabirafusp-ted and KSI-101 forming its late-stage portfolio.

Consensus target stays near the quote

Seven analysts give KOD a consensus rating of Strong Buy and an average 12-month price target of USD 96.33, which is 1.99 percent above USD 94.45, according to Stockanalysis. The same page lists a 52-week range of USD 10.94 to USD 104.00, placing the last quote USD 9.55 below the yearly high.

UBS raised its target from USD 80.00 to USD 120.00 and kept a Buy rating on September 28, while Jefferies set a USD 112.00 Buy target, according to MarketBeat. These targets frame the debate after the trial result, but they do not remove the clinical and financing risks attached to an unapproved pipeline.

KOD remains below its yearly high

Kodiak Sciences stock was last at USD 94.45 on Nasdaq on October 2, 2026, at 4:00 p.m. EDT, after a USD 4.01 daily decline. Market capitalization was USD 5.9 billion, and volume reached 2,672,738 shares.